Mar. Drugs 2012, 10(6), 1297-1306; doi:10.3390/md10061297
Quinazolin-4-one Coupled with Pyrrolidin-2-iminium Alkaloids from Marine-Derived Fungus Penicillium aurantiogriseum
1
CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China
2
Graduate University of Chinese Academy of Sciences, Beijing 100049, China
3
Hisun Pharmaceutical Co. Ltd., Taizhou 318000, China
†
These authors contributed equally to this work.
*
Author to whom correspondence should be addressed.
Received: 9 April 2012 / Revised: 29 May 2012 / Accepted: 29 May 2012 / Published: 7 June 2012
Abstract
Three new alkaloids, including auranomides A and B (1 and 2), a new scaffold containing quinazolin-4-one substituted with a pyrrolidin-2-iminium moiety, and auranomide C (3), as well as two known metabolites auranthine (4) and aurantiomides C (5) were isolated from the marine-derived fungus Penicillium aurantiogriseum. The chemical structures of compounds 1–3 were elucidated by extensive spectroscopic methods, including IR, HRESIMS and 2D NMR spectroscopic analysis. The absolute configurations of compounds 1–3 were suggested from the perspective of a plausible biosynthesis pathway. Compounds 1–3 were subjected to antitumor and antimicrobial screening models. Auranomides A–C exhibited moderate cytotoxic activity against human tumor cells. Auranomides B was the most potent among them with an IC50 value of 0.097 μmol/mL against HEPG2 cells. View Full-Text
Figure 1
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).
Share & Cite This Article
MDPI and ACS Style
Song, F.; Ren, B.; Yu, K.; Chen, C.; Guo, H.; Yang, N.; Gao, H.; Liu, X.; Liu, M.; Tong, Y.; Dai, H.; Bai, H.; Wang, J.; Zhang, L. Quinazolin-4-one Coupled with Pyrrolidin-2-iminium Alkaloids from Marine-Derived Fungus Penicillium aurantiogriseum. Mar. Drugs 2012, 10, 1297-1306.
Related Articles
Article Metrics
Comments
[Return to top]
Mar. Drugs
EISSN 1660-3397
Published by MDPI AG, Basel, Switzerland
RSS
E-Mail Table of Contents Alert